NCT05933161Recruiting

A Study of Glycemic Control in Left Ventricular Assist

Mayo Clinic

Start Date

11/10/2023

Completion Date

7/1/2027

Summary

The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010 * Diagnosis of type II diabetes mellitus * Any antihyperglycemic regimen * Greater than 3 months out from LVAD implantation * Capable of utilizing smartphone device for LibreLink app for uploading glycemic data * Patients may be enrolled who have preexisting CGM in place. Exclusion Criteria: * Type I diabetics * Unable to return at 3 month evaluation * Unwillingness to participate

Interventions

DEVICE

Freestyle Libre 3 Continuous Glucose Monitor (CGM)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Type 2 Diabetes MellitusHyperglycemiaHypoglycemia

Locations

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States